Cardiovascular Research Advance Access [Accepted Manuscript] published online on April 5, 2008
Cardiovascular Research, doi:10.1093/cvr/cvn093
Insulin signalling in the heart
1 Université catholique de Louvain, Division of cardiology, Brussels, Belgium
2 Université catholique de Louvain, de Duve Institute, Hormone and Metabolic Research Unit, Brussels, Belgium
Send correspondence to: Luc Bertrand, Université catholique de Louvain, CARD Unit, 55, Avenue Hippocrate, CARD5550, 1200, Brussels, Belgium. Tel: +32 2 764 55 52, Fax +32 2 764 55 36, E-mail: luc.bertrand{at}uclouvain.be, website: http://www.card.ucl.ac.be/
The main role of insulin in the heart under physiological conditions is obviously the regulation of substrate utilization. Indeed, insulin promotes glucose uptake and its utilization via glycolysis. In addition, insulin participates in the regulation of long-chain fatty acid uptake, protein synthesis and vascular tonicity. Significant advancements have been made over the last 20 years in the understanding of the signal transduction elements involved in these insulin effects. Amongst these molecular mechanisms, the phosphatidylinositol 3-kinase/protein kinase B (Akt) pathway is thought to play a crucial role. Under pathological conditions, such as type-2 diabetes, myocardial ischemia and cardiac hypertrophy, insulin signal transduction pathways and action are clearly modified. These molecular signalling alterations are often linked to atypical crosstalks with other signal transduction pathways. On the other hand, pharmacological modifications of parallel and interdependent signalling components, such as the AMP-activated protein kinase pathway, is now considered to be a good therapeutic approach to treat insulin signalling defects such as insulin resistance and type-2 diabetes. In this review, we will focus on the description of the molecular signalling elements involved in insulin action in the heart and vasculature under these different physiological, pathological and therapeutical conditions.
KEYWORDS Energy metabolism; PKB/Akt; ischemia; protein synthesis; insulin resistance; AMPK
Time for primary review: 21 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Basu, G. Y. Oudit, X. Wang, L. Zhang, J. R. Ussher, G. D. Lopaschuk, and Z. Kassiri Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function Am J Physiol Heart Circ Physiol, December 1, 2009; 297(6): H2096 - H2108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Liu, J. Han, S. Y. Cao, T. Hong, D. Zhuo, J. Shi, Z. Liu, and W. Cao Hepatic Autophagy Is Suppressed in the Presence of Insulin Resistance and Hyperinsulinemia: INHIBITION OF FoxO1-DEPENDENT EXPRESSION OF KEY AUTOPHAGY GENES BY INSULIN J. Biol. Chem., November 6, 2009; 284(45): 31484 - 31492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-S. Tsou, V. Addanki, J. A. Haas, N. A. Page, and H.-L. Fung Role of Glutaredoxin-Mediated Protein S-Glutathionylation in Cellular Nitroglycerin Tolerance J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 649 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Youn, T. Wang, and H. Cai An Ezrin/Calpain/PI3K/AMPK/eNOSs1179 Signaling Cascade Mediating VEGF-Dependent Endothelial Nitric Oxide Production Circ. Res., January 2, 2009; 104(1): 50 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Vaughan-Jones and P. Swietach Pushing and Pulling the Cardiac Sodium/Hydrogen Exchanger Circ. Res., October 10, 2008; 103(8): 773 - 775. [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Lopaschuk and D. P. Kelly Signalling in cardiac metabolism Cardiovasc Res, July 15, 2008; 79(2): 205 - 207. [Full Text] [PDF]
|
|